Here, we demonstrate an miRNA‐independent mechanism of TARBP2, in which downregulation of the TARBP2 protein promotes sorafenib resistance in HCC cells through stabilization of Nanog expression. The gene discussed is TARBP2; the disease is hepatocellular carcinoma.